VTRS Viatris Inc.
Mergers ·
Viatris agreed to buy Pacira for $36.50 a share in cash, an equity value of $1.65 billion, through a tender offer and a second-step merger. The release states no premium to the recent share price.
Viatris (Nasdaq: VTRS) and unnamed current and former officers are defendants in a Pennsylvania class action over Indore disclosures. Derivative suits name officers and directors in Pennsylvania and Delaware.
Viatris signed a ¥40,000,000,000 senior unsecured term loan with Mizuho Bank, Ltd. as administrative agent. The proceeds may repay a 2021 loan of the same size, and the company reported a net loss of $3.51 billion for 2025.
Viatris completed a €650,000,000 offering of 4.250% senior notes due 2033 on June 17, 2026. The proceeds first repay June revolver borrowings used to pay off $1.675 billion of 2026 notes, and the company reported a 2025 net loss of $3.51 billion. The 8-K names no underwriter.
Viatris is offering €650,000,000 of 4.250% senior notes due 2033 to repay revolving credit borrowings drawn to retire its 2026 notes. Its 2025 net loss was $3.51 billion.
After an enterprise-wide strategic review, Viatris committed to restructuring that it expects to cut its global workforce by up to approximately 10%. It expects potential savings of between $600 million and $700 million.
Viatris is a global healthcare company that supplies generics, including complex products, globally recognized brands and an expanding portfolio of innovative medicines. It operates in more than 165 countries and territories, with 27 manufacturing, packaging and distribution sites and more than 1,400 approved molecules. Its 2025 total revenues were $14.30 billion. The company reported five positive Phase 3 data readouts in 2025. These included MR-107A-02, a fast-absorbing formulation of meloxicam for moderate-to-severe acute pain, LYNX-2 for MR-142 (phentolamine ophthalmic solution) in night driving impairment, and VEGA-3 for MR-141 in presbyopia, whose supplemental NDA was accepted in February 2026. A low-dose estrogen weekly dermal patch has an NDA accepted under the FDA's 505(b)(2) pathway with a target action date of July 30, 2026. Other pipeline assets include selatogrel and cenerimod, which remain on track for enrollment. Viatris also received the first approval for Inpefa (sotagliflozin) in the United Arab Emirates and launched it in early 2026. Its Iron Sucrose Injection launched in the U.S. in 2025.
| Product or program | What it is | Stage |
|---|---|---|
| MR-107A-02 (meloxicam) | Fast-absorbing meloxicam for moderate-to-severe acute pain | positive Phase 3 top-line results |
| Low-dose estrogen weekly dermal patch | Contraceptive patch with norelgestromin and ethinyl estradiol | NDA accepted; target action date July 30, 2026 |
| MR-141 (phentolamine ophthalmic solution) | Treatment for presbyopia | supplemental NDA accepted February 2026; FDA action expected in the second half of 2026 |
| MR-142 (phentolamine ophthalmic solution) | Treatment for chronic night driving impairment in keratorefractive patients | positive Phase 3 LYNX-2 results |
| Inpefa (sotagliflozin) | Medicine for markets outside the U.S. and Europe | first approval in the United Arab Emirates; launched early 2026 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $14.30 billion | $14.74 billion |
| Net income (loss) | -$3.51 billion | -$634.2 million |
| Cash from operations | $2.32 billion | $2.30 billion |
| Cash and equivalents | $1.32 billion | $734.8 million |
| Short-term investments | $40.7 million | $38.0 million |
Our latest story on this, dated Aug 6, 2026: "Viatris faces Indore plant securities class action and derivative suits in two federal courts". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 18, 2026: "Viatris completes €650,000,000 public offering of 4.250% senior notes due 2033". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 8, 2026: "Viatris agrees to acquire Pacira BioSciences for $36.50 per share in cash". The story links the filing or release it is based on. Read the story.
Viatris Inc. trades under the ticker VTRS on NASDAQ.
Viatris Inc. is listed on NASDAQ. Our directory also records these other listings: BIVA:VTRS; BMV:VTRS; DUS:VIA; EUROTLX:4VTRS; FWB:VIA; GETTEX:VIA; HAM:VIA; HAN:VIA; LS:A2QAME; LSIN:0A5V; LSX:A2QAME; MUN:VIA; SIX:VTRS; SWB:VIA; TRADEGATE:VIA; VIE:VTRS; XETR:VIA.
The SEC Central Index Key (CIK) for Viatris Inc. is 1792044. Its filings are on SEC EDGAR.
1,148,590,864 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Viatris Inc. under United States.
Our directory classifies Viatris Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Viatris Inc. is US92556V1061.
aibio.space lists Viatris Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Viatris is a global healthcare company that supplies generics, including complex products, globally recognized brands and an expanding portfolio of innovative medicines. It operates in more than 165 countries and territories, with 27 manufacturing, packaging and distribution sites and more than 1,400 approved molecules.
MR-107A-02 (meloxicam): Fast-absorbing meloxicam for moderate-to-severe acute pain Stage: positive Phase 3 top-line results.
Low-dose estrogen weekly dermal patch: Contraceptive patch with norelgestromin and ethinyl estradiol Stage: NDA accepted; target action date July 30, 2026.
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,8.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio